Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24046845 | 0.81 | GRM5 (0.33) | GRM5GAACCR1RAB9ACCR5 | |
| SCHEMBL22048899 | 0.78 | GRM5 (0.51) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL382392 | 0.78 | GRM5 (0.51) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL20870315 | 0.77 | GRM5 (0.48) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL18237835 | 0.77 | GRM5 (0.48) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL12415835 | 0.77 | GRM5 (0.45) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL2669705 | 0.76 | FABP6 (0.42) | GRM5 | |
| SCHEMBL21382705 | 0.74 | GRM5 (0.62) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL14476027 | 0.74 | GRM5 (0.48) | GRM5ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL30947103 | 0.74 | GRM5 (0.62) | GRM5ALDH1A1GAAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-3402777-A1 | OXAZOLIDINONES AS TARO INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2017106138-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | GRM5 1799/4885ALDH1A1 312/4885GAA 220/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GRM5 2711/4885ALDH1A1 2151/4885GAA 36/4885 |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRM5 887/4885ALDH1A1 3839/4885GAA 15/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GRM5 446/4885ALDH1A1 2260/4885GAA 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.